http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-538491-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00 |
| filingDate | 2003-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9926b20b72fd16c45a67755b2529f601 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25755f1ea8ab6253d443ea7aff4a9f24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_267dfc5deae250a51ce441c1327df1b9 |
| publicationDate | 2007-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-538491-A |
| titleOfInvention | Novel prodrugs of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-YL-carboxylic acid-(N-2-pyridil-N-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments |
| abstract | The disclosure relates to compounds of general formula (I) wherein (a) R' denotes a hydrogen atom and R denotes a methoxycarbonyl group or (b) R' denotes a hydrogen atom or a C1-6 -alkyl group and R denotes a hydroxy group, where the alkyl groups which contain more than 2 carbon atoms also include the branched isomers thereof, the tautomers and the salts thereof, especially the salts thereof which are physiologically compatible with inorganic or organic acids or bases, exhibiting valuable properties, especially a thrombin inhibiting effect. Specific examples of the compounds of formula (I) are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, a tautomer and a salt thereof; and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide, a tautomer and a salt thereof. |
| priorityDate | 2002-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.